For research use only
| Cat No. | ABC-TC0215 |
| Product Type | Human Lung Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Small Cell Cancer |
| Product Code | DMS-454; DMS454 |
Research DMS 454, Human small cell lung carcinoma from a Caucasian male, isolated in 1981, suitable for cancer biology and drug discovery research.
DMS-454 is a human small cell lung carcinoma (SCLC) cell line derived from the lung tissue of a Caucasian male patient during autopsy. These cells display polygonal epithelial morphology, adhere loosely in culture and contain dense-core vesicles, secreting calcitonin, common for SCLC. Cytogenetically, DMS-454 cells display a complex hyperdiploid karyotype with multiple structural abnormalities. Like other classic SCLC models, they harbor TP53; Simple; p. Val157Phe (c. 469G>T) and RB1 mutations. DMS-454 cells are highly tumorigenic in immunodeficient mice and are frequently used to model chemoresistance and neuroendocrine plasticity in SCLC. Their gene expression profile also reveals overexpression of oncogenes such as MYC family members, which are critical in SCLC progression and are commonly grouped within broader DMS cancer model classifications in comparative SCLC research.
| Product Code | DMS-454; DMS454 |
| Species | Human |
| Cat.No | ABC-TC0215 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Small Cell Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
DMS-454 is a valuable model for studying small-cell lung cancer and developing new therapies for these patients. For example, the utilization of DMS-454 provides an opportunity to identify the tumor markers specific to small cell lung cancer (SCLC) in the initial stage. Once these markers are identified, the next step involves assessing the effectiveness of antibodies targeting these markers within the context of CAR-T cell therapy. This approach aims to determine whether the antibodies can effectively engage the markers and initiate the desired immune response to eliminate cancer cells.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
